

SOCS3 (L210) Antibody

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W	H M R	Endogenous	26	Rabbit	#O14543	9021

Product Usage Information**Application**

Western Blotting

Dilution

1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody.

Specificity/Sensitivity

SOCS3 (L210) Antibody detects endogenous levels of total SOCS3 protein.

Species predicted to react based on 100% sequence homology

Monkey, Bovine, Dog

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu210 of SOCS3. Antibodies were purified by protein A and peptide affinity chromatography.

Background

The suppressor of cytokine signaling (SOCS) family members are negative regulators of cytokine signal transduction that inhibit the Jak/Stat pathway (1-3). The SOCS family consists of at least 8 members including the originally identified cytokine-inducible SH2-containing protein (CIS1), as well as SOCS1-7. Each SOCS family member contains a central SH2 domain and a conserved carboxy-terminal motif designated as the SOCS box. These proteins are important regulators of cytokine signaling, proliferation, differentiation, and immune responses. Low levels of SOCS3 are observed in lung, spleen and thymus and, like other SOCS family members, its expression is rapidly induced by a number of factors including interleukins, EPO, IFN-γ, CSF and TNF-α (4). SOCS3 uses its SH2 domain to bind activated Jaks and their cognate receptors to provide negative feedback inhibition. In addition to the initially described inducers of SOCS3 expression, subsequent studies have described SOCS3-mediated negative feedback inhibition for leptin (5), GH (6), chemokine receptors (7), insulin (8), and certain pathogens (9,10). SOCS3 deletion results in embryonic lethality with placental insufficiency (11). SOCS3 signaling has been linked pathologically to allergic responses (12), inflammatory disease (13), endotoxic shock (14), wound repair (15), and obesity (16,17).

Background References

- Alexander, W.S. et al. (1999) *J Leukoc Biol* 66, 588-92.
- Chen, X.P. et al. (2000) *Immunity* 13, 287-90.
- Hilton, D.J. et al. (1998) *Proc Natl Acad Sci USA* 95, 114-9.
- Starr, R. et al. (1997) *Nature* 387, 917-21.
- Bjørbaek, C. et al. (1998) *Mol Cell* 1, 619-25.
- Adams, T.E. et al. (1998) *J Biol Chem* 273, 1285-7.
- Soriano, S.F. et al. (2002) *J Exp Med* 196, 311-21.
- Emanuelli, B. et al. (2000) *J Biol Chem* 275, 15985-91.
- Stoiber, D. et al. (1999) *J Immunol* 163, 2640-7.
- Stoiber, D. et al. (2001) *J Immunol* 166, 466-72.
- Roberts, A.W. et al. (2001) *Proc Natl Acad Sci USA* 98, 9324-9.
- Seki, Y. et al. (2003) *Nat Med* 9, 1047-54.
- Shouda, T. et al. (2001) *J Clin Invest* 108, 1781-8.
- Fang, M. et al. (2005) *Cell Mol Immunol* 2, 373-7.
- Goren, I. et al. (2006) *J Invest Dermatol* 126, 477-85.
- Mori, H. et al. (2004) *Nat Med* 10, 739-43.
- Howard, J.K. et al. (2004) *Nat Med* 10, 734-8.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting

Cross-Reactivity Key

H: Human **M:** Mouse **R:** Rat

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.